Onco-Innovations Limited (CVE:ONCO)

PRESS RELEASE

published on 07/12/2025 at 00:00, 10 months 6 days ago

Onco-Innovations Signs Agreement with Redwood AI to Advance Discovery and Evaluation of Its PNKP Inhibitor Technology
Onco-Innovations partners with Redwood AI for drug development, leveraging AI-driven chemistry tools to enhance cancer therapy with PNKP Compound. Vancouver-based collaboration aims to improve research efficiency

Cancer Therapy Onco-Innovations PNKP Compound Redwood AI AI-driven Chemistry
BRIEF

published on 07/11/2025 at 00:05, 10 months 7 days ago

Onco-Innovations Appoints Dr. Islam Mohamed as Advisory Board Chair

Biotechnology Advisory Board Oncology Cancer Research Dr. Islam Mohamed
BRIEF

published on 07/11/2025 at 00:05, 10 months 7 days ago

Onco-Innovations nomme le Dr Islam Mohamed à la présidence de son conseil consultatif

Biotechnologie Conseil Consultatif Oncologie Recherche Sur Le Cancer Dr Islam Mohamed
PRESS RELEASE

published on 07/11/2025 at 00:00, 10 months 7 days ago

Onco-Innovations Strengthens Clinical Leadership with Appointment of Dr. Islam Mohamed as Advisory Board Chair
Onco-Innovations Limited appoints Dr. Islam Mohamed as Chair of Scientific and Clinical Advisory Board, highlighting commitment to oncology research excellence and innovation acceleration

Scientific Advisory Board Oncology Research Onco-Innovations Limited Dr. Islam Mohamed Clinical Advisory Board
BRIEF

published on 07/05/2025 at 00:05, 10 months 13 days ago

Onco-Innovations Partners with Nucro-Technics for Preclinical Studies

Cancer Treatment Preclinical Studies Onco-Innovations PNKP Inhibitor Nucro-Technics
BRIEF

published on 07/05/2025 at 00:05, 10 months 13 days ago

Onco-Innovations s'associe à Nucro-Technics pour des études précliniques

Traitement Du Cancer Etudes Précliniques Onco-Innovations Nucro-Techniques Inhibiteur De La PNKP
PRESS RELEASE

published on 07/05/2025 at 00:00, 10 months 13 days ago

Onco-Innovations Enters Agreement with Nucro-Technics for IND-Enabling Studies, Taking a Key Step Toward Human Trials
Onco-Innovations partners with Nucro-Technics for preclinical studies on PNKP inhibitor, critical step towards human trials. Strategic collaboration with GLP and GMP experienced CRO

Clinical Trials Preclinical Studies Onco-Innovations PNKP Inhibitor Nucro-Technics
BRIEF

published on 07/03/2025 at 00:35, 10 months 15 days ago

Onco-Innovations Reveals Strategic Developments in Investor Call

Artificial Intelligence Cancer Treatment Strategic Milestones Onco-Innovations PNKP Inhibitor
BRIEF

published on 07/03/2025 at 00:35, 10 months 15 days ago

Onco-Innovations dévoile ses développements stratégiques lors d'une conférence téléphonique avec les investisseurs

Intelligence Artificielle Traitement Du Cancer Étapes Stratégiques Onco-Innovations Inhibiteur De PNKP
PRESS RELEASE

published on 07/03/2025 at 00:30, 10 months 15 days ago

Onco-Innovations CEO Highlights Strategic Milestones and R&D Progress in Special Investors' Conference Call
Onco-Innovations updates strategic roadmap for cancer treatment innovation, highlighting AI partnerships and research collaborations

Cancer Treatment Strategic Roadmap AI Partnerships Onco-Innovations Research Collaborations

Published on 05/17/2026 at 15:20, 15 hours 35 minutes ago

China XLX Announces 2026 Q1 Results
Published on 05/16/2026 at 01:15, 2 days 5 hours ago

Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 01:00, 2 days 5 hours ago

Arctic Fox Adopts Semi-Annual Reporting
Published on 05/16/2026 at 00:00, 2 days 6 hours ago

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 2 days 7 hours ago

Golden Minerals Reports First Quarter 2026 Financial Results

View all ACCESSWIRE

Published on 05/18/2026 at 06:30, 25 minutes ago

Helvetica Swiss Living Fund – Review of a Capital Increase
Published on 05/18/2026 at 06:30, 25 minutes ago

Helvetica Swiss Living Fund – examen d’une augmentation de capital
Published on 05/16/2026 at 16:08, 1 day 14 hours ago

The publication of the audited financial statements for 2025 will be postponed to 12 June 2026 – management does not expect any significant changes to the figures already published
Published on 05/15/2026 at 20:10, 2 days 10 hours ago

CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:30, 2 days 12 hours ago

Designated Person Notifications

View all EQS

Published on 05/15/2026 at 15:08, 2 days 15 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 2 days 15 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 2 days 20 hours ago

Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 3 days 21 hours ago

Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 4 days 12 hours ago

ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES

View all LES ECHOS COMFI WIRE

News